Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

NCT04178798 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia- Binet Staging System

Interventions

DRUG: Acalabrutinib 100 MG Oral Capsule

Sponsor

PETHEMA Foundation